Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

Recruiting

Phase 1

FLAG-Ida & PVEKCombination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

Sponsor:

Fred Hutchinson Cancer Center

Code:

NCT06034470

Conditions

Acute Myeloid Leukemia

Mixed Phenotype Acute Leukemia

Myelodysplastic Syndrome

Myelodysplastic/Myeloproliferative Neoplasm

Myeloproliferative Neoplasm

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Bone Marrow Aspiration

Bone Marrow Biopsy

Cytarabine

Echocardiography

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-23. This information was provided to ClinicalTrials.gov by Fred Hutchinson Cancer Center on 2025-08-12.